Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

Patients with certain types of early stage cancer, particularly those affecting the gastrointestinal system, may be able to ...

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

The increase is due to a $11.0 million increase in royalties recognized for sales of Jemperli and $9.6 million in revenue recognized for the Vanda license agreement. Research and development ...

A new, groundbreaking clinical trial has shown results that may soon replace surgery and other treatments like chemotherapy ...

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery ...

What if your body’s own immune system could be taught to wipe out tumours — and do it so effectively that no further ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient ...